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Renal hemodynamics and pharmacokinetics of bosentan with namic effects induced by cyclosporine, and has been con-
and without cyclosporine A. sidered a mediator of its nephrotoxicity. ET induces renal
Background. Endothelins may play an important role in
vasoconstriction and has mitogenic properties that mightcyclosporine A (CsA)-induced renal vasoconstriction. There-
play a role in the fibrosis observed in chronic toxicityfore, the effects of a mixed endothelin A and B receptor antago-
nist, bosentan (BO), on CsA were studied. [1]. In vitro, cyclosporine induces the release of ET from
Methods. BO was given either alone or combined with CsA rat smooth muscle cells [2, 3], as well as the synthesis of
to healthy subjects in a double-blind, placebo-controlled, cross-
ET in cultured human endothelial cells and proximalover study. Standardized renal hemodynamics took place after
tubular cells [4, 5]. In experimental animal models, prom-a single dose of BO or placebo and after seven days of regular
intake of CsA 1 BO or CsA 1 placebo. CsA was administered ising results have been obtained with anti-ET antibodies
as a dose-adjusted regimen to achieve predetermined target or ET receptor antagonists showing reversal of the
trough levels. A pharmacokinetic study of CsA and BO was
cyclosporine-induced renal vasoconstriction [6–8]. In hu-performed.
man studies, the infusion of ET-1, an ET-A and ET-BResults. A single dose of BO did not affect renal hemody-
namics. After seven days of coadministration with CsA, BO receptor agonist, induced a decrease in glomerular filtra-
significantly attenuated both the overall CsA-induced fall of tion rate (GFR) and renal plasma flow (RPF), suggestingrenal plasma flow (RPF; placebo, 594 6 85; CsA 1 placebo,
that the receptors indeed play a role in the regulation490 6 93; CsA 1 BO, 570 6 106* mL/min, *P , 0.01) and
the maximal RPF fall (P , 0.01) observed five hours after of renal vasoconstriction in humans [9, 10].
CsA intake. The CsA-induced rise of blood pressure and the In the field of transplantation, nephrotoxicity is an
decrease of glomerular filtration rate (GFR) were not influ- important problem associated with cyclosporine therapy,enced by comedication with BO. After seven days of CsA 1
and the attenuation of the renal vasoconstriction wouldBO, the area under the curve (AUC) of BO was nearly doubled
compared with the AUC after a single dose of BO (P , 0.05). be of clinical relevance. Therefore, we investigated the
To reach the CsA target trough levels after seven days, the effects of bosentan (BO), a nonpeptide-mixed ET-A and
average CsA dose was increased by 35% when given with BO,
ET-B receptor antagonist, given alone and in combina-as compared with placebo (P 5 0.01). CsA exposure (trough
tion with cyclosporine A (CsA) to healthy individuals;levels, AUC) was not statistically different after CsA 1 placebo
and after CsA 1 BO. the study design mimicked a post-transplantation situa-
Conclusions. Assuming CsA nephrotoxicity is mainly due tion. The aim of this study was to determine whetherto vasoconstriction, BO has the potential to attenuate the CsA
BO inhibited the renal hemodynamic effects induced byrenal toxicity by markedly blunting the renal hypoperfusion
effect of CsA. A complex drug interaction between BO and CsA in humans, and to investigate a possible pharmaco-
CsA was observed. kinetic interaction between the two drugs.
Since the early 1990s, the endothelin (ET) system has METHODS
been more and more incriminated in the renal hemody-
Study design
The study consisted of a randomized, double-blind, pla-Key words: endothelin receptor agonist, vasoconstriction, renal plasma
cebo-controlled, and cross-over administration of a mixedflow, nephrotoxicity, hypoperfusion.
ET-A and ET-B receptor antagonist, BO (Ro 47-0203)
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daily at the dose of 500 mg starting at day 1 in the
morning until day 8. Two subjects initially received 1000
mg twice daily, but for tolerance reasons (headache and
nausea), the dose was reduced to 500 mg twice daily
from day 3 until day 8. Another subject initially received
500 mg twice daily, but the dosage had to be reduced to
250 mg twice daily between day 5 and day 7 because
of tolerance problems; however, this subject was not
excluded from the study and received the regular dose
of 500 mg for the functional evaluation on day 8.
CsA was given as Sandimmun Neoralt (SN) capsules
300 mg twice daily starting from the day 1 evening dose,
together with the second dose of BO or placebo, so as
not to interfere with the day 1 functional evaluation.
CsA was administered until day 8. A dose adjustment
was performed on day 3 and day 5 according to the 12-
hour trough level. Target trough concentrations (Ctr)Fig. 1. Study design.
were set between 200 and 250 ng/mL. The dose adjust-
ment for SN was based on the CsA-Ctr measured just
before the administration of the morning dose of daysboth cross-over treatment periods. Figure 1 shows the
3 and 5, respectively, and started with the evening doseoverall study design. On days 1 and 8 of each period, a
of days 3 and 5, respectively. The dose adjustment wasrenal hemodynamic study (clearance) and a pharmacoki-
not performed randomly but according to a predeter-netic evaluation of BO and CsA were performed. The
mined scheme given in Table 1.day 1 clearance investigated the effects of a single dose of
BO or of placebo alone. The results from the day 1 clear- Apart from the morning dose of day 1, where BO was
ance with placebo served as baseline values (placebo 5 given alone, CsA and BO were administered at the same
baseline), and those from the day 1 clearance with BO time, morning and evening, throughout the rest of the
represented the acute effect of a single dose of the ET study period.
receptor antagonist. The day 8 clearance represented the
effects of regular administration over seven days of CsA Clearance assessment
alone (CsA 1 placebo) or BO with CsA (CsA 1 BO). Renal hemodynamics were assessed on days 1 and 8
The study protocol was reviewed and approved by the of each period according to an exactly identical proce-
local ethics committee.
dure. An inulin (Inutestt; Laevosan International Ltd.)
and paraaminohippuric acid (PAH; Nephrotestt; BAGSubjects
Med. Ltd.) infusion was then started and continued overTen male volunteers entered the study; their mean
eight hours. The first 60 minutes of continuous inulinage was 25 years (range 20 to 28 years). Based on medical
and PAH infusion were used for equilibration. Thereaf-history, physical examination, and routine laboratory
ter, the following hemodynamic parameters were mea-tests, all subjects were healthy with a normal body weight
sured at regular hourly intervals during seven hours(77.9 6 6.2 kg, body mass index 22.9 6 1.4 kg/m2, range
21.2 to 25.0). Seven subjects completed the two periods (once for each of the 7 clearance periods): systolic and
and were thus available for the functional study evalua- diastolic blood pressure (SBP and DBP) and inulin, cre-
tion. atinine, and PAH clearances (CIn, CCr, CPAH).
From the total of 10 subjects who entered the study, The inulin concentration in blood and urine was deter-
three did not complete both periods. Two were with- mined by a fructose isomerase reaction, PAH by a so-
drawn because of a drug-dispensing error and one be- dium nitrate diazotization. CIn was used to calculate thecause of tolerance problems. These three subjects were GFR, and CPAH was used for the measurement of theexcluded from the hemodynamic analysis but remained
renal plasma flow (RPF).included in the safety analysis.
The filtration fraction (FF) was calculated as:A written informed consent was obtained from each
subject before his or her participation to the study. FF 5 (GFR/RPF) 3100
Drug administration To calculate the renal vascular resistance (RVR), the
hematocrit was measured every two hours, and the for-An oral suspension of BO (Hoffmann-La Roche Ltd.,
Nutley, NJ, USA) or placebo was administered twice mula used was as follows:
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Table 1. Sandimmun Neoral (SN) pre-determined dose-adjustment regimen according to 12 hour cyclosporine
(CsA)-trough levels (Ctr) on day 3 and day 5
Day 3 Day 5
Ctr ng/mL SN dose-adjustment Ctr ng/mL SN dose-adjustment
,100 ↑ by 2 350 mg/day ,150 ↑ by 2 350 mg/day
$100 and #149 ↑ by 2 325 mg/day $150 and #199 ↑ by 2 325 mg/day
$150 and #250 no change $200 and #250 no change
$251 and #300 ↓ by 2 325 mg/day $251 and #300 ↓ by 2 325 mg/day
.300 ↓ by 2 350 mg/day .300 ↓ by 2 350 mg/day
RVR 5 (mean arterial BP/RPF) 3 (1 2 hematocrit) terminal half-life (t1/2), and trough blood level of CsA
(Ctr). In addition, a dose-corrected Cmax, Ctr, and AUCBlood samples were taken at the midpoint of each
were calculated for CsA because the subjects receivedclearance hour. At the end of each clearance hour, the
different doses of CsA in order to reach the target Ctr.subjects spontaneously voided their bladder, and urinary
samples were taken. During each clearance assessment, Statistical method
approximately 2 L (50% glucose 5% and 50% NaCl
The sample size for this study was chosen to estimate0.9%) were infused according to the body weight of each
the effect on GFR with sufficient precision based on ansubject.
estimated coefficient of variation in a study of SturrockThe subject’s oral hydration consisted in 1 L of drink-
et al [12], allowing a judgment of whether the safetying water during the 12 hours prior to clearance start,
margin of 25 mL/min was not exceeded. Although onlyfollowed by 250 mL/h during the eight clearance hours.
seven volunteers completed both study periods, the safetyIn all occasions, the protein and salt intake were stan-
margin was not exceeded for GFR or for RPF values.dardized in the evening and during the night before each
Results are expressed as a mean value 6 sd of theclearance day, as well as during the whole clearance
pooled results obtained for the seven subjects duringmeasurements; the total amount reached 9.3 g of salt
all seven clearance periods. The values in the figuresand 76 g of protein. Between days 1 and 8, the food and
represent the mean values 6 sem of the seven subjectsdrinking water intake were free.
for each of the seven clearance periods. A three-way
analysis of variance was used to test for differencesPharmacokinetic assessments
between the results of the seven clearance periods onOn days 1 and 8 of each treatment period, the pharma-
day 1 (placebo as baseline and BO single dose) and oncokinetics of BO were evaluated, and plasma levels were
day 8 (CsA 1 placebo and CsA 1 BO). A 95% confi-measured at time 0 (before the first dose or 12 h after
dence interval was calculated. Statistical significance wasthe last dose), at 30 minutes, and at 1, 2, 4, 6, 8, 10, and
reached for values of P , 0.05.12 hours after the morning dose. Plasma concentrations
To test for differences between the pharmacokineticsof BO were measured by a specific high-performance
of BO on days 1 and 8, Cmax, AUC, and t1/2 for BO wereliquid chromatography method with ultraviolet detec-
compared using the Student’s t-test for paired samples.tion (HPLC-UV) and a quantitation limit of 50 ng/mL,
To test for differences in the CsA pharmacokineticsas previously described [11].
(Cmax, AUC, t1/2, Ctr) between CsA 1 BO and CsA 1On the morning of days 3 and 5, CsA Ctr were mea-
placebo, a three-way analysis of variance was performedsured 12 hours after the last SN intake for the purpose
using the measured, the dose-corrected parameters andof dose adjustment. On day 8 of each treatment period,
the factors treatment, period, sequence, and subjects. Log-the pharmacokinetics of CsA were performed, and blood
transformed values for Cmax, Ctr, and AUC were used.levels were measured at time 0 (12 h after the last SN
administration), at 30 minutes, and at 1, 2, 4, 6, 8, 10,
and 12 hours after the morning dose. The whole blood RESULTS
concentration of CsA was measured using a commer-
Blood pressurecially available CsA monoclonal immunoassay (Abbott
Table 2 and Figure 2 show the values of SBP and DBPDiagnostics TDxt).
measured during the four clearance days. All subjectsPharmacokinetic evaluation was performed with model-
were normotensive on baseline with a mean pressure ofindependent methods. The following parameters were
126/72 mm Hg (range SBP, 122 to 130; DBP, 68 to 75).calculated: peak plasma or blood concentration (Cmax),
After a single dose of BO, both SBP and DBP slightlytime to reach Cmax (tmax), area under the curve (AUC
(0-∞) for day 1 and AUC (0 to 12 h) for day 8, apparent decreased on average to 123/69 mm Hg. Only the DBP
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Table 2. Results of systolic and diastolic blood pressure (sBP, dBP), was less marked (0.111 6 0.007). This difference almost
glomerular filtration rate (GFR), and renal plasma flow (RPF)
reached statistical significance (P 5 0.06).during clearance assessments
Compared with baseline, a single dose of BO lowered
sBP dBP GFR RPF the FF from 20.3 6 2.0% to 18.0 6 2.2% (P , 0.01).
mm Hg mL/min After seven days of CsA 1 placebo, the FF was margin-
Placebo (baseline) 12669 7268 120619 594685 ally elevated to 21.3 6 3.1. The combined chronic intake
BO single dose 123 69 6966a 111620 6206123 of CsA 1 BO significantly reduced the FF to 18.1 6
CsA 1 placebo 7 days 13566b 8064b 103618c 490693c
2.3% (P , 0.01), and this was caused by the persistenceCsA 1 BO 7 days 136 68 8067 103620 570 6106d
of the CsA-induced GFR fall while the RPF fall wasData are mean values 6 sd of the subjects over all clearance periods
a P , 0.05 BO single dose vs. placebo single dose mostly blunted.
b P , 0.001 CsA 1 placebo seven days vs. placebo single dose
c P , 0.05 CsA 1 placebo seven days vs. placebo single dose
Pharmacokineticsd P , 0.01 CsA 1 BO seven days vs. CsA 1 placebo seven days
The pharmacokinetic evaluations after a single dose
of BO and after seven days CsA 1 BO are detailed in
Table 3. The half-life of BO (t1/2) was not modified bydecrease reached statistical significance (P , 0.05). After seven days of coadministration with CsA. The maximal
seven days of regular intake of CsA 1 placebo, a signifi- concentration (Cmax) of BO was increased by the co-cant rise of the SBP and DBP to 135/80 was observed medication with CsA, but this did not reach statistical
(P , 0.001). Values were comparable under CsA 1 BO significance. There was a trend toward significant increase
(Fig. 2). Thus, adding BO to CsA did not attenuate the of the time necessary for reaching the maximal concen-
CsA-induced rise of blood pressure. tration (tmax) of BO when given with CsA as compared
with a single dose of BO (P 5 0.06). The AUC of BORenal hemodynamics
significantly increased by 1.7-fold after seven days of
Table 2 gives the results of the mean renal hemody- CsA 1 BO (P , 0.05). This was clinically suspected based
namics values obtained during the four clearance days. on the side effects that appeared under coadministration
The baseline GFR was 120 6 90 mL/min and remained of 2 3 1000 mg/day BO and SN in the first two subjects.
stable after a single dose of BO. CsA 1 placebo during As a consequence, the BO dosage was reduced by half.
seven days caused a significant fall of GFR to 103 6 The pharmacokinetic parameters of CsA on day 8 are
18 mL/min (P , 0.05), which was not modified by BO shown in Table 4. The results for Cmax, Ctr, tmax, and t1/2
comedication (CsA 1 BO, 103 6 20 mL/min). Figure 3 were comparable after seven days of CsA 1 BO and
shows the GFR values obtained for each clearance hour CsA 1 placebo. Also, the real AUCs, as measured in
and demonstrates that the CsA 1 placebo curve was the subjects during the day 8 kinetic evaluation in both
almost identical to the CsA 1 BO curve. study periods, were comparable (P 5 0.2). However,
The baseline RPF of 594 6 85 mL/min was not altered when this real AUC was corrected for the dose of CsA,
by a single dose of BO. After seven days of CsA 1 the AUC/dose ratio was significantly different between
placebo, the RPF was markedly reduced to 490 6 93 the CsA 1 placebo and the CsA 1 BO kinetics (P 5
mL/min (P , 0.05), thus representing a mean flow reduc- 0.002). The discrepancy between the real AUC and the
tion of approximately 100 mL/min (Table 2). As repre- corrected AUC, that is, the AUC/dose ratio, revealed
sented on Figure 4, the RPF globally decreased during the necessity for CsA dose adjustment in the presence
each clearance hour and showed a further peak reduction of BO. If the appropriate dose adjustment had not taken
during the fourth clearance period. This maximum re- place, BO would have reduced the AUC for CsA by 49%
duction in RPF occurred around five hours after the SN and the Ctr by 62%, a statistically significant decrease of
intake and 3.5 hours after the peak CsA-blood concen- the CsA exposure.
tration. With coadministration of CsA 1 BO during
Tolerance of the studyseven days, the mean RPF was significantly higher (570 6
106 mL/min) than with CsA 1 placebo (P , 0.01) and Neither the administration of CsA alone nor of BO
reached values almost comparable to baseline. Not only alone induced serious adverse events during the study.
was the overall flow set at a higher level throughout the However, several side effects, mainly headache, nausea,
CsA 1 BO clearance assessment, but the maximal flow and vomiting, occurred during the combined treatment
reduction, which occurred at the fourth hour, was also with CsA 1 BO and were related to BO. They were of
blunted (Fig. 4). sufficient severity in the first two subjects to lead to a
The RVR was not affected by a single dose of BO. dose reduction of BO from 1000 to 500 mg twice daily
RVR increased from 0.091 6 0.007 at baseline to 0.124 6 for the rest of the study, even before plasma levels were
0.017 after seven days of CsA 1 placebo (P 5 0.01). available. In one case, the side effects led to a withdrawal
from the study. Tolerance of the combined treatment im-After seven days of CsA 1 BO, the increase in RVR
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Fig. 2. Systolic/diastolic blood pressure. Mean
results (6 sem) of hourly blood pressure mea-
surements during clearance assessment after
placebo (d; baseline), seven days of CsA 1
placebo (m), and seven days of CsA 1 BO
regular intake (j).
Fig. 3. Glomerular filtration rate. Mean re-
sults (6 sem) of hourly inulin clearance after
placebo (d; baseline), seven days of CsA 1
placebo (m), and seven days of CsA 1 BO
regular intake (j).
proved after three days. Acral dysesthesias were observed we could confirm that CsA decreased the GFR and RPF
during the CsA 1 placebo regimen, and were related to values in healthy individuals and in patients, as has been
the higher than target levels for CsA trough values; the shown by other groups in animal models [6, 12, 13]. In
symptoms resolved after appropriate CsA dose reduction. the present study, CsA lowered the RPF on average
by 104 mL/min, but there was also an additional peak
decrease five hours after SN intake and 3.5 hours afterDISCUSSION
the peak CsA blood concentration (Fig. 4). Figure 3This study was designed to mimic a post-transplant
suggests a similar but more modest peak decrease in thesituation in which BO would be administered with CsA
GFR curve four hours after CsA intake. The phenome-to attenuate CsA toxicity. The potential of BO to prevent
non of a peak fall in the RPF and GFR profiles hasthe CsA-associated renal toxicity is based on the knowl-
already been described by Perico et al in a renal hemody-edge that CsA increases the preglomerular vascular tone,
namic investigation of kidney-transplanted patients [13].which might be regulated by the endogenous production
In their study, the maximal decline occurred six hoursof ETs. An ET receptor antagonist may therefore attenu-
after CsA intake and two to four hours after the maximalate the CsA toxicity, as has been suggested by animal
blood concentration. The galenic difference betweendata [7, 8].
Regarding the effects of CsA on renal hemodynamics, Sandimmun and SN could account for the more rapid
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Fig. 4. Renal plasma flow. Mean results
(6 sem) of hourly PAH clearance after pla-
cebo (d; baseline), seven days of CsA 1 pla-
cebo (m), and seven days of CsA 1 BO regular
intake (j).
absorption and thus the earlier peak hypoperfusion after In the present study, the addition of BO to CsA had
different consequences on the RPF than the GFR. Basedintake observed in our subjects.
The most impressive effect of BO in our study was on the experience in rats [6–8], we expected the ET
receptor antagonist to prevent the CsA-induced reduc-observed on the RPF. The fall of RPF measured after
seven days of regular BO and CsA coadministration was tion of both GFR and RPF. However, we found that
the effects of BO added to CsA seemed to be mainlysignificantly attenuated compared with seven days of
CsA alone. Moreover, the RPF remained almost at base- restricted to the RPF, whereas the CsA-induced fall of
GFR was not influenced (Fig. 3). These renal hemody-line values when BO was added to CsA. Not only was
the whole curve shifted toward a higher perfusion flow namics suggest that BO mainly relieved the vasoconstric-
tive effect of CsA on the efferent arteriole and lowered(Fig. 4), but the peak hypoperfusion five hours after SN
intake was also significantly blunted. The effect of BO the glomerular capillary pressure similar to an angioten-
sin-converting enzyme inhibitor exerting an efferent va-on the maximal decrease of RPF occurred shortly after
the time of maximal blood concentration of BO (tmax). sodilation. In contrast, Lanese and Conger demonstrated
on isolated rat renal arterioles that a selective ET-AThus, we found that BO limited the overall CsA-induced
renal hypoperfusion and the twice-daily occurring peak antagonist completely blocked the vasoconstrictive ef-
fect of CsA on the afferent arteriole but did not affectRPF fall.
Furthermore, BO showed a trend toward limiting the the CsA-induced efferent vasoconstriction [16]. These
discrepancies could be related to differences in receptorCsA-induced increase of RVR. Because BO had no ef-
fect on the rise in blood pressure, its effect on the vascular distribution and receptor function in the kidney among
different species [17] as well as methodological differ-tone must have been predominant on the renal vascula-
ture. This is in agreement with the knowledge that the ences like the use of a selective ET-A versus a mixed
ET-A and ET-B receptor antagonist. The ET-B receptorrenal vascular bed is the most sensitive to the vasocon-
strictor effect of ET [14]. has complex functions that are still not totally elucidated
in humans, and it is probably up-regulated by CsA [18].Assuming that the main mechanism of cyclosporine
toxicity is renal vasoconstriction, our findings regarding It has been suggested that endogenous ET is a compo-
nent of the systemic vascular tone [19], and it is knownRPF and RVR support the hypothesis that BO indeed
has the potential to attenuate this side effect. Whether that ET-1 induces systemic vasoconstriction [10]. Thus,
antagonizing the ET receptors would be expected to leador not this functional effect would correlate with the
prevention of the histopathologic findings of CsA neph- to vasodilation and a decrease in blood pressure. This
was indeed the case in our study in that a single dose ofrotoxicity is a question beyond the scope of our investiga-
tion. However, a study in a rat model of chronic CsA- BO caused a small but significant reduction in DBP. CsA
is known to increase blood pressure, and this was alsoinduced renal damage showed that the administration
of a selective ET-A antagonist improved renal function the case in our study. BO has been recently demonstrated
to significantly lower DBP in patients with essential hy-but did not improve structural damage [15].
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Table 3. Pharmacokinetics of bosentan (BO) after a single dose and after 7 days of co-administration with cyclosporine A (CsA)
tmax t1/2 Cmax AUC
Parameters hours ng/mL ng*h/mL
BO single dose 2.9 61.2 3.3 61.0 474362315 24,780613,280
(1.0–4.0) (2.1–5.6) (2134–9262) (8646–48,660)
CsA 1 BO 7 days 4.3 62.1 3.4 61.1 791664276 48,900624,130
(2.0–8.0) (2.1–4.7) (3555–15,700) (25,720–85,400)
P value 0.06 0.88 0.08 0.04
Mean values 6 sd (range). AUC, area under the curve.
Table 4. Pharmacokinetic parameters of CsA after 7 days of co-administration with placebo or BO
tmax t1/2Dose Cmax Cmax/dose Ctr Ctr/dose AUC AUC/dose
Parameters mg ng/mL ng/mL/mg ng/mL ng/mL/mg ng*h/mL ng*h/mL/mghours
CsA 1 placebo 208618 1.7 60.5 15.864.2 13626326 6.661.8 3096130 1.560.7 781962411 38.1 613.1
(200–250) (1.0–2.1) (11.8–22.8) (887–1828) (3.6–9.1) (178–623) (0.7–3.1) (5090–13,348) (20.4–66.7)
CsA 1 BO 322631 1.4 60.5 14.063.4 15126191 4.760.7 194650 0.660.2 652061283 20.5 65.2
(275–375) (1.0–2.1) (9.7–19.8) (1098–1736) (3.7–5.8) (137–266) (0.4–0.9) (4604–8062) (14.2–29.3)
P value 0.01 0.7 0.6 0.2 0.007 0.07 0.003 0.2 0.002
Data are mean values 6 sd (range).
pertension, to an extent comparable with angiotensin- if the exposure to CsA had not been comparable at the
end of both study periods. The study was designed inconverting enzyme inhibitors [20]. However, BO did not
influence the CsA-induced rise of blood pressure in our order to reach CsA target trough levels as usually is the
case under clinical conditions and identical target troughhealthy subjects. As discussed by Sturrock et al [12], we
believe that the cyclosporine-induced arterial hyperten- levels at the end of the two study periods, that is, CsA
with and without BO. The particular study design al-sion is likely to be an ET-independent mechanism, which
does not preclude a different blood pressure-lowering lowed reachable comparable exposure to CsA in both
groups. If the appropriate SN dose adjustment had noteffect of BO on essential hypertension. In fact, one ani-
mal study suggested that BO could reduce the blood taken place, the exposure to CsA (AUC) at the end of
the CsA 1 BO period would have been approximatelypressure in CsA-hypertensive rats and primates [21].
However, the group of animals treated with CsA and half of the exposure reached at the end of the CsA 1
placebo period. However, because of the CsA dose-BO had significantly lower CsA blood levels at the end
of the experiment compared with the group treated with adjustment regimen, there was no statistical difference
in CsA trough levels and real AUC at the end of bothCsA and placebo. Therefore, rather than a demonstra-
tion of BO effectiveness in reducing blood pressure, this periods. Thus, the protective effects of the ET antagonist
can be interpreted as an intrinsic property of BO andsuggests that an indirect effect of BO exists secondary
to the marked lowering of CsA levels. The lowering of not as a consequence of a lower exposure to CsA. Ex-
pressing the pharmacokinetic parameters as a dose-cor-CsA levels by BO was also observed in our study, but
the CsA dose adjustment resulted in a comparable CsA rected ratio showed the effect of the interaction between
BO and CsA and emphasized the need for dose adjust-exposure in the BO-treated group as in the placebo
group at the end of the study periods. ment according to trough levels.
To our knowledge, the pharmacological interactionOne could argue that no effect on the blood pressure
of our subjects was observed because the BO levels were between BO and CsA has not been previously investi-
gated, but could have been suspected based on the sharednot high enough, leading to an incomplete receptor
blockade caused by an up-regulation of the ET-receptors metabolism of both drugs through the cytochrome P450
system. In vitro experiments with human liver micro-[17, 22, 23]. This is unlikely because BO blood levels were
higher than expected, and thus well above the minimal somes and hepatocytes have shown that BO induces
certain cytochrome P450 hepatic isoenzymes, amongblocking concentration [24]. A further hypothesis to ex-
plain the lacking effect of the mixed ET-A and ET-B others CYP 3A4 (personal communication, C. Weber).
This isoenzyme is responsible for BO’s own metabolism,antagonist could be a balance between vasodilation caused
by ET-A blockade and vasoconstriction caused by ET-B as well as for CsA metabolism. Thus, the enzymatic in-
duction should lead to an increased metabolism of bothblockade [22, 25], resulting in no net effect.
The validity of our results could have been questioned BO and CsA, and therefore to decreased plasma and
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5. Ong ACM, Jowett TP, Scoble JE, O’Shea JA, Varghese Z,blood concentration. Indeed, if BO is given alone, its
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3A4, a competitive enzymatic inhibition by CsA leads 7. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal
vasoconstriction induced by cyclosporine in the rat. J Am Socto a decreased metabolism of BO, but still increased
Nephrol 1:76–83, 1990metabolism of CsA when both drugs are administered
8. Fogo A, Hellings SE, Ianagami T, Kon V: Endothelin receptor
together. This would explain the increase of BO levels antagonism is protective in in vivo acute cyclosporine toxicity.
Kidney Int 42:770–774, 1992concomitant to the decrease of CsA levels in our study,
9. Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B,requiring significant dose adjustments during the com-
Koomans HA: Effects of endothelin-1 on renal function in humans:bined administration. Based on this knowledge, addi- Implications for physiology and pathophysiology. Kidney Int
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